Market Overview

UPDATE: Bank of America Initiates Neutral, $29 PO on The Medicines Company; Pipeline Uncertain

Share:
Related MDCO
Eagle Pharma Has 'Several Upcoming Catalysts' And Is A Buy, RBC Says
The Medicines Company Announces FDA Approval of KENGREAL as an Adjunct to Percutaneous Coronary Intervention for Reducing Thrombotic Events
Seeking Alpha's Biotech Weekly: Celgene-Juno, Gilead's HIV NDA, Happy 4th! (Seeking Alpha)

Bank of America initiated its coverage on The Medicines Company (NASDAQ: MDCO) with a Neutral rating and a price target of $29.

Bank of America noted, "MDCO is a profitable company focused on hospital-based drugs, with its key product Angiomax, the dominant anti-coagulant used in US angioplasty procedures (PCI). Our NPV estimate for Angiomax with assumed generic entry in 2019 is $24/sh, with another $4.50 for net cash. We attribute minimal risk-adjusted value for MDCO's late-stage pipeline products due to upcoming binary phase 3 results near year-end that in our view represent meaningful upside and downside drivers to the stock. If near-term phase 3 results are unfavorable, we would expect MDCO to pursue bolt-on acquisitions of hospital-based products."

The Medicines Company closed at $25.08 on Tuesday.

Latest Ratings for MDCO

DateFirmActionFromTo
May 2015Leerink SwannMaintainsOutperform
May 2015JP MorganMaintainsOverweight
Apr 2015CitigroupMaintainsNeutral

View More Analyst Ratings for MDCO
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (MDCO)

Around the Web, We're Loving...

Get Benzinga's Newsletters